Bioelectronic Medicine Startup Raises $180M Series C

On the morning of November 12, 2024, Elena Marsh sat in a glass-walled conference room in Emeryville, California, and watched a wire transfer confirmation land in her company’s bank account. It read $180,000,000. Marsh is the cofounder and chief executive of Corvus Neurotech, a seven-year-old bioelectronic medicine company that has spent the last three years trying to convince the FDA, and a rotating cast of skeptical biotech investors, that a nerve implant the size of a shirt button can do something no biologic drug has managed: shut down the inflammatory flares of Crohn’s disease without touching the rest of the immune system.

The round, a Series C led by Action Potential Venture Capital and ARCH Venture Partners, with participation from Deerfield Management, is one of the largest single financings the bioelectronic medicine field has seen. It will fund a pivotal trial of Corvus’s implant, which wraps around the splenic nerve bundle near the celiac plexus and delivers programmed electrical pulses designed to suppress the release of tumor necrosis factor, the same inflammatory signaling molecule that biologic drugs like infliximab and adalimumab are built to block chemically.

The science behind the device is not new. What is new is that someone is finally willing to spend nine figures proving it works at the scale the FDA requires for approval, rather than the scale required for a compelling conference poster.

A Second Act for the Cholinergic Anti-Inflammatory Pathway

The biology Corvus is betting on traces back to a set of experiments Kevin Tracey ran at the Feinstein Institutes for Medical Research in the late 1990s. Tracey’s group found that electrically stimulating the vagus nerve suppressed the release of TNF-alpha during sepsis, and that cutting the nerve made inflammation worse. The 2000 paper describing the mechanism, published in Nature by Tracey’s collaborator Lars Borovikova, gave the phenomenon a name that has since become a small industry: the cholinergic anti-inflammatory pathway.

The circuit works through an indirect route that took another decade to fully map. Signals traveling down the vagus nerve activate the splenic nerve, which releases norepinephrine into the spleen. That norepinephrine acts on a population of T cells that, unusually, synthesize acetylcholine. The acetylcholine then binds to alpha-7 nicotinic receptors on macrophages, the immune cells responsible for churning out TNF, and tells them to stand down. Mauricio Rosas-Ballina and colleagues at Feinstein described this T-cell relay in a 2011 Science paper that remains one of the field’s most cited pieces of evidence that the nervous system talks to the immune system in specific, targetable language.

The spleen doesn’t decide to get inflamed. A nerve tells it to.

SetPoint Medical, based in Valencia, California, was the first company to turn this biology into an implant aimed at a specific disease. Its vagus nerve stimulator for rheumatoid arthritis produced results in a 2016 study led by Frieda Koopman and published in the Proceedings of the National Academy of Sciences, showing measurable drops in TNF production and disease severity in patients who had failed conventional drugs. Bruno Bonaz’s group at Grenoble Alpes University Hospital ran a parallel pilot study of vagus nerve stimulation in Crohn’s disease patients around the same period, reporting symptom improvement over six months of continuous stimulation. Corvus’s approach diverges from both by stimulating the splenic nerve directly rather than the vagus trunk, a narrower target that Marsh says reduces off-target effects on heart rate and voice, two side effects that have complicated vagus nerve stimulation trials for decades.

Why Investors Are Betting on Circuits Instead of Molecules

Bioelectronic medicine has always had an awkward relationship with venture capital. The science is old and well replicated in animal models, but the path from a working circuit to an implantable product cleared for humans is longer and more expensive than most drug development timelines, not shorter. A pill can be manufactured in a factory that already exists. An implantable neurostimulator needs its own manufacturing line, its own battery chemistry, its own surgical training program, and its own reimbursement code before a single patient benefits from it.

Investors are backing circuits, not molecules.

That calculus has started to shift. Action Potential Venture Capital, the investment arm GSK spun out specifically to fund bioelectronic medicine, has spent close to a decade building a thesis around the idea that chronic inflammatory disease is fundamentally a wiring problem for a meaningful subset of patients, not just a molecular one. ARCH Venture Partners, which built its reputation on deep biology bets that took a decade or more to pay off, has increasingly treated neuromodulation the way it once treated gene therapy: expensive, slow, and worth it if the mechanism is real. Deerfield Management’s participation signals something more mundane but just as important, that a healthcare-focused crossover investor believes the Corvus device could plausibly reach commercial revenue within a normal fund’s investment horizon.

Marsh frames the pitch in blunt terms. Biologic drugs for Crohn’s disease cost tens of thousands of dollars a year, work for a minority of patients long term, and carry systemic immunosuppression risks that show up as infections and, rarely, lymphomas. A device that is implanted once, requires no refills, and suppresses inflammation only in the anatomical circuit responsible for gut inflammation is, in her words, “a different kind of drug that never leaves the pharmacy shelf broken.”

The Regulatory Shortcut That Made This Round Possible

Corvus’s device received FDA Breakthrough Device Designation in 2022, a program created to speed review of technologies that address unmet needs in serious conditions. The designation does not guarantee approval, but it does guarantee more frequent, more substantive interaction with FDA reviewers during development, which matters enormously for a device category where the agency has approved very few comparable products and has limited institutional precedent to draw on.

The company’s earlier feasibility study, run at a small number of U.S. sites, was funded by its $42 million Series B in 2021. That study was never designed to prove efficacy at a level the FDA would accept for approval. It was designed to prove the implant could be placed safely, that patients would tolerate the surgery, and that the device could be titrated without the cardiovascular side effects that dogged earlier vagus nerve stimulation attempts. The $180 million now in hand is earmarked almost entirely for a single purpose: a pivotal trial large enough, and long enough, to generate the kind of data that ends up in a product label rather than a journal supplement.

That is a meaningfully different spending plan than most Series C rounds in bioelectronic medicine, which historically have gone toward manufacturing scale-up or international expansion after a product already has some regulatory clearance. Corvus is spending its biggest round yet before it has any clearance at all, a bet that reflects both confidence in the mechanism and the sheer cost of running device trials with implantation surgery, ongoing programming visits, and years of follow-up built into the protocol.

A Crowded, Cautious Field

Corvus is not alone in trying to convert nerve circuits into approved products, and the field’s track record so far is mixed enough to explain why investors have been cautious until now. Galvani Bioelectronics, the joint venture GSK and Verily launched in 2016 with the explicit goal of mapping nerve-to-organ circuits and commercializing them as “electroceuticals,” spent years working largely out of public view before narrowing its pipeline to a smaller number of indications. Iota Biosciences, the University of California, Berkeley spinout known for its millimeter-scale “neural dust” motes, was acquired by Astellas Pharma in 2022 rather than pursuing an independent path to market, a sign that even sophisticated engineering teams have found the regulatory and commercial climb easier to make inside a large pharmaceutical company than outside one. Neuros Medical, developing a peripheral nerve stimulator for post-amputation pain called Altius, has had more momentum, moving through FDA review on the strength of a mechanism that is easier to validate: block a pain signal, measure whether the pain goes down.

What separates Corvus from most of that list is the specificity of its bet. Rather than building a platform meant to eventually address a menu of inflammatory diseases, the company has committed its largest financing round to a single indication and a single nerve target. That is a narrower path than Galvani’s original ambitions, and a riskier one than Neuros Medical’s more mechanically straightforward pain-blocking approach. It is also, Marsh argues, the only way a device company survives long enough to reach the market: prove one thing works completely before promising the platform can do everything.

What a Pivotal Trial Actually Has to Prove

The trial Corvus is now funding will need to answer questions that a feasibility study never has to touch. Regulators will want to know whether the reduction in inflammatory markers translates into meaningful, durable improvement in the specific clinical measures gastroenterologists use to define Crohn’s disease remission, not just a drop in C-reactive protein on a lab report. They will want years of follow-up data on device longevity, since an implant that fails after eighteen months creates a different risk profile than a biologic infusion a patient can simply stop. And they will want to see whether the narrower splenic nerve target actually delivers on its promise of fewer systemic side effects compared with the broader vagus nerve stimulation approaches that preceded

Credit: Mindfield Biosystems on Unsplash